{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:57:55Z","timestamp":1792457875018,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013116","name":"Merz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013116","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40120-026-00991-3","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:13:12Z","timestamp":1783419192000},"page":"2689-2705","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Inhaled Levodopa for the Management of OFF Episodes in Patients with Parkinson\u2019s Disease: A Network Meta-analysis"],"prefix":"10.1007","volume":"15","author":[{"given":"Omar","family":"Madani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan","family":"Mistry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rushab","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Chattey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Guerra Primo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne C.","family":"Gadeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Perni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ubong","family":"Silas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg-Alexander","family":"Pietsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"H\u00f6glinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"991_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.14108","volume":"27","author":"R Balestrino","year":"2020","unstructured":"Balestrino R, Schapira AHV. Parkinson disease. Eur J Neurol. 2020;27:27\u201342.","journal-title":"Eur J Neurol"},{"key":"991_CR2","doi-asserted-by":"publisher","first-page":"S255","DOI":"10.37765\/ajmc.2020.88517","volume":"26","author":"C Tanner","year":"2020","unstructured":"Tanner C. Exploring the clinical burden of OFF periods in Parkinson disease. Am J Manag Care. 2020;26:S255\u201364.","journal-title":"Am J Manag Care"},{"key":"991_CR3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2217\/cer-2021-0178","volume":"11","author":"A Thach","year":"2022","unstructured":"Thach A, et al. Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson\u2019s disease \u2018OFF\u2019 episodes. J Com Eff Res. 2022;11:285\u201395.","journal-title":"J Com Eff Res"},{"key":"991_CR4","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/mds.20279","volume":"20","author":"S Chapuis","year":"2005","unstructured":"Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson\u2019s disease on the quality of life. Mov Disord. 2005;20:224\u201330.","journal-title":"Mov Disord"},{"key":"991_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.parkreldis.2020.07.003","volume":"78","author":"LP Prizer","year":"2020","unstructured":"Prizer LP, et al. The presence of a caregiver is associated with patient outcomes in patients with Parkinson\u2019s disease and atypical parkinsonisms. Parkinsonism Relat Disord. 2020;78:61\u20135.","journal-title":"Parkinsonism Relat Disord"},{"key":"991_CR6","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/ana.410260209","volume":"26","author":"ST Gancher","year":"1989","unstructured":"Gancher ST, Woodward WR, Boucher B, Nutt JG. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol. 1989;26:232\u20138.","journal-title":"Ann Neurol"},{"key":"991_CR7","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1002\/mds.28726","volume":"36","author":"CW Olanow","year":"2021","unstructured":"Olanow CW, Poewe W, Rascol O, Stocchi F. On-demand therapy for OFF episodes in Parkinson\u2019s disease. Mov Disord. 2021;36:2244\u201353.","journal-title":"Mov Disord"},{"key":"991_CR8","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1001\/archneur.58.9.1385","volume":"58","author":"RB Dewey Jr","year":"2001","unstructured":"Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA. A Randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for Parkinsonian off-state events. Arch Neurol. 2001;58:1385.","journal-title":"Arch Neurol"},{"key":"991_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2147\/NDT.S273121","volume":"19","author":"N Masood","year":"2023","unstructured":"Masood N, Jimenez-Shahed J. Effective management of \u201cOFF\u201d episodes in Parkinson\u2019s disease: emerging treatment strategies and unmet clinical needs. Neuropsychiatr Dis Treat . 2023;19:247\u201366.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"991_CR10","doi-asserted-by":"publisher","first-page":"360ra136","DOI":"10.1126\/scitranslmed.aad8858","volume":"8","author":"MM Lipp","year":"2016","unstructured":"Lipp MM, Batycky R, Moore J, Leinonen M, Freed MI. Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson\u2019s disease. Sci Transl Med. 2016;8:360ra136.","journal-title":"Sci Transl Med"},{"key":"991_CR11","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1093\/advances\/nmab060","volume":"12","author":"JT Boelens Keun","year":"2021","unstructured":"Boelens Keun JT, Arnoldussen IA, Vriend C, van de Rest O. Dietary approaches to improve efficacy and control side effects of levodopa therapy in Parkinson\u2019s disease: a systematic review. Adv Nutr. 2021;12:2265\u201387.","journal-title":"Adv Nutr"},{"key":"991_CR12","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2147\/PPA.S301644","volume":"15","author":"A Thach","year":"2021","unstructured":"Thach A, et al. Patient preferences for treating \u201cOFF\u201d episodes in Parkinson\u2019s disease: a discrete choice experiment. PPA. 2021;15:1187\u201396.","journal-title":"PPA"},{"key":"991_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105859","volume":"116","author":"E Camgrand","year":"2023","unstructured":"Camgrand E, et al. Discontinuation rate and long-term adverse events path of apomorphine infusion in advanced Parkinson\u2019s disease patients. Parkinsonism Relat Disord. 2023;116:105859.","journal-title":"Parkinsonism Relat Disord"},{"key":"991_CR14","volume-title":"NICE DSU Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials","author":"S Dias","year":"2014","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. London: National Institute for Health and Care Excellence (NICE); 2014."},{"key":"991_CR15","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/0303-8467(93)90128-4","volume":"95","author":"T Van Laar","year":"1993","unstructured":"Van Laar T, et al. A double-blind study of the efficacy of apomorphine and its assessment in \u2018off\u2019-periods in Parkinson\u2019s disease. Clin Neurol Neurosurg. 1993;95:231\u20135.","journal-title":"Clin Neurol Neurosurg"},{"key":"991_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S1474-4422(19)30396-5","volume":"19","author":"CW Olanow","year":"2020","unstructured":"Olanow CW, et al. Apomorphine sublingual film for off episodes in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol. 2020;19:135\u201344.","journal-title":"Lancet Neurol"},{"key":"991_CR17","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","volume":"17","author":"R Katzenschlager","year":"2018","unstructured":"Katzenschlager R, et al. Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018;17:749\u201359.","journal-title":"Lancet Neurol"},{"key":"991_CR18","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1002\/mds.26611","volume":"31","author":"PA LeWitt","year":"2016","unstructured":"LeWitt PA, et al. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson\u2019s disease. Mov Disord. 2016;31:1356\u201365.","journal-title":"Mov Disord"},{"key":"991_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1474-4422(18)30405-8","volume":"18","author":"PA LeWitt","year":"2019","unstructured":"LeWitt PA, et al. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2019;18:145\u201354.","journal-title":"Lancet Neurol"},{"key":"991_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1089\/jamp.2016.1354","volume":"31","author":"PA LeWitt","year":"2018","unstructured":"LeWitt PA, et al. Pulmonary safety and tolerability of inhaled levodopa (CVT-301) administered to patients with Parkinson\u2019s disease. J Aerosol Med Pulm Drug Deliv. 2018;31:155\u201361.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"991_CR21","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40120-021-00251-6","volume":"10","author":"F Agbo","year":"2021","unstructured":"Agbo F, et al. Pharmacokinetics and comparative bioavailability of apomorphine sublingual film and subcutaneous apomorphine formulations in patients with Parkinson\u2019s disease and \u201cOFF\u201d episodes: results of a randomized, three-way crossover. Open-Label Study Neurol Ther. 2021;10:693\u2013709.","journal-title":"Open-Label Study Neurol Ther"},{"key":"991_CR22","doi-asserted-by":"crossref","unstructured":"M\u00fcller Th, Benz S, B\u00f6rnke Ch, Muhlack S, Woitalla D, Przuntek H. Worsened motor test performance following acute apomorphine injection in previously untreated patients with Parkinson\u2019s disease. In: Muller Th, Riederer P, editors. Focus on extrapyramidal dysfunction. Vol. 68. Berlin: Springer Nature; 2004. p. 79\u201387.","DOI":"10.1007\/978-3-7091-0579-5_9"},{"key":"991_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/WNF.0000000000000111","volume":"38","author":"M Nomoto","year":"2015","unstructured":"Nomoto M, et al. A randomized controlled trial of subcutaneous apomorphine for Parkinson disease: a repeat dose and pharmacokinetic study. Clin Neuropharmacol. 2015;38:241\u20137.","journal-title":"Clin Neuropharmacol"},{"key":"991_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.parkreldis.2006.06.012","volume":"13","author":"RF Pfeiffer","year":"2007","unstructured":"Pfeiffer RF, Gutmann L, Hull KL, Bottini PB, Sherry JH. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson\u2019s disease. Parkinsonism Relat Disord. 2007;13:93\u2013100.","journal-title":"Parkinsonism Relat Disord"},{"key":"991_CR25","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1474-4422(15)00007-1","volume":"14","author":"A Fasano","year":"2015","unstructured":"Fasano A, Visanji NP, Liu LWC, Lang AE, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson\u2019s disease. Lancet Neurol. 2015;14:625\u201339.","journal-title":"Lancet Neurol"},{"key":"991_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.parkreldis.2019.12.012","volume":"71","author":"DG Grosset","year":"2020","unstructured":"Grosset DG, et al. Inhaled levodopa in Parkinson\u2019s disease patients with OFF periods: a randomized 12-month pulmonary safety study. Parkinsonism Relat Disord. 2020;71:4\u201310.","journal-title":"Parkinsonism Relat Disord"},{"key":"991_CR27","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.parkreldis.2012.01.001","volume":"18","author":"WG Ondo","year":"2012","unstructured":"Ondo WG, et al. Apomorphine injections: predictors of initial common adverse events and long term tolerability. Parkinsonism Relat Disord. 2012;18:619\u201322.","journal-title":"Parkinsonism Relat Disord"},{"key":"991_CR28","doi-asserted-by":"publisher","first-page":"82","DOI":"10.36469\/jheor.2021.29488","volume":"8","author":"A Thach","year":"2021","unstructured":"Thach A, et al. Cost-effectiveness of apomorphine sublingual film as an \u2018On-Demand\u2019 treatment for \u2018OFF\u2019 episodes in patients with Parkinson\u2019s disease. J Health Econ Outcomes Res. 2021;8:82\u201392.","journal-title":"J Health Econ Outcomes Res"},{"key":"991_CR29","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1007\/s00415-024-12323-2","volume":"271","author":"J Kassubek","year":"2024","unstructured":"Kassubek J, et al. Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson\u2019s disease complicated by OFF episodes: a phase 3, open-label study. J Neurol. 2024;271:3554\u201370.","journal-title":"J Neurol"},{"key":"991_CR30","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/mdc3.70074","volume":"12","author":"M Aubignat","year":"2025","unstructured":"Aubignat M, Khelifi F, Rascol O, the NS\u2010PARK\/FCRIN Network. Use of and barriers to subcutaneous apomorphine pen injections in Parkinson\u2019s disease: a survey by the French NS\u2013PARK Network. Movement Disord Clin Pract. 2025;12:1211\u20133.","journal-title":"Movement Disord Clin Pract"},{"key":"991_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-023-00589-8","volume":"9","author":"W Sako","year":"2023","unstructured":"Sako W, et al. Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson\u2019s disease\u2014network meta-analysis. NPJ Parkinson\u2019s Dis. 2023;9:143.","journal-title":"NPJ Parkinson's Dis"},{"key":"991_CR32","unstructured":"Stocchi F, Olanow C, Peckham E, et al. Dose optimization of apomorphine sublingual film for on-demand treatment of \u201cOFF\u201d episodes in patients with Parkinson\u2019s Disease: Clinical and exposure response findings. Mov Disord. 2020;35(S1)."},{"key":"991_CR33","doi-asserted-by":"crossref","unstructured":"Hauser RA, Olanow CW, Dzyngel B, et al. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson\u2019s disease: Sublingual Apomorphine Film Strip in PD. Mov Disord. 2016;31(9):1366\u201372.","DOI":"10.1002\/mds.26697"},{"key":"991_CR34","doi-asserted-by":"crossref","unstructured":"Hui JS, Fox SH, Neeson W, et al. Open-label titration of apomorphine sublingual film in patients with Parkinson\u2019s disease and \u201cOFF\u201d episodes. Parkinsonism Relat Disord. 2020;79:110\u20136.","DOI":"10.1016\/j.parkreldis.2020.08.028"},{"key":"991_CR35","doi-asserted-by":"crossref","unstructured":"Isaacson S, Lew M, Ondo W, Hubble J, Clinch T, Pagan F. Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson\u2019s Disease. Mov Disord Clin Pract. 2017;4(1):78\u201383.","DOI":"10.1002\/mdc3.12350"},{"key":"991_CR36","doi-asserted-by":"crossref","unstructured":"Graham JS, Henderson JM, Morris JGL, Yiannikas C. A comparison of standard Madopar and controlled release Madopar in Parkinson\u2019s disease. Aust N Z J Med. 1991;21(S1):11\u20135.","DOI":"10.1111\/j.1445-5994.1991.tb02994.x"},{"key":"991_CR37","doi-asserted-by":"crossref","unstructured":"Katzenschlager R, Poewe W, Rascol O, et al. Long-term safety and efficacy of apomorphine infusion in Parkinson\u2019s disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study. Parkinsonism Relat Disord. 2021;83:79\u201385.","DOI":"10.1016\/j.parkreldis.2020.12.024"},{"key":"991_CR38","doi-asserted-by":"crossref","unstructured":"Ondo W, Hunter C, Almaguer M, Jankovic J. A novel sublingual apomorphine treatment for patients with fluctuating Parkinson\u2019s disease. Mov Disord. 1999;14(4):664\u20138.","DOI":"10.1002\/1531-8257(199907)14:4<664::AID-MDS1017>3.0.CO;2-5"},{"key":"991_CR39","doi-asserted-by":"crossref","unstructured":"Farbman ES, Waters CH, LeWitt PA, et al. A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson\u2019s disease. Parkinsonism Relat Disord. 2020;81:144\u201350.","DOI":"10.1016\/j.parkreldis.2020.10.029"},{"key":"991_CR40","doi-asserted-by":"crossref","unstructured":"Diamond SG, Markham CH, Treciokas LJ. A double\u2010blind comparison of levodopa, madopa, and sinemet in Parkinson disease. Ann Neurol. 1978;3(3):267\u201372.","DOI":"10.1002\/ana.410030314"},{"key":"991_CR41","doi-asserted-by":"crossref","unstructured":"Stocchi F, Fabbri L, Vecsei L, Krygowska-Wajs A, Monici Preti PA, Ruggieri SA. Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease. Clin Neuropharmacol. 2007;30(1):18\u201324.","DOI":"10.1097\/01.WNF.0000236762.77913.C6"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00991-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00991-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00991-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:03:34Z","timestamp":1790381014000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00991-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["991"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00991-3","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Omar Madani, Chetan Mistry, Rushab Shah, Grace Chattey, Leandro Guerra Primo, Hanne C Gadeberg, Stefano Perni and G\u00fcnter H\u00f6glinger have no competing interest other than the study being funded by Merz\u00a0Therapeutics\u00a0GmbH. Ubong Silas, Carmen Walter and Georg-Alexander Pietsch are employees of Merz\u00a0Therapeutics\u00a0GmbH.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}